Navigation Links
Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
Date:10/10/2007

CALL DATE: Oct. 31, 2007 TIME: 8:30 a.m. Eastern Time HOST: Dr. Candace

Kendle, Chairman and CEO

CINCINNATI, Oct. 10 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL) will conduct a telephone conference call and simultaneous webcast Oct. 31 at 8:30 a.m. Eastern Time to discuss its financial results for the Third Quarter 2007. A question and answer session will follow.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

Webcast Instructions

To access the live webcast, go to http://www.kendle.com or http://www.videonewswire.com/event.asp?id=43011. Instructions for accessing the webcast are provided at both sites. The webcast will be archived at http://www.kendle.com (click on "Investors") shortly after the call for on-demand replay through 5 p.m. Eastern Time on Nov. 30, 2007. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.

Conference Call Instructions

To register (RSVP) for the telephone conference call, U.S. and Canadian participants should dial (800) 223-7104. Participants outside North America should dial (706) 645-6519.

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on Nov. 30 by dialing (706) 645-9291 and entering conference ID number 5447273.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations and is the fourth-largest provider of Phase II-IV clinical development services worldwide. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. With the expertise of our more than 3,000 associates worldwide, Kendle has conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Biomedical engineering conference invites manufacturers
2. Dispelling the top five myths about attending networking events
3. UW engineering career fair sees highest attendance in four years
4. Visions: Broderick says Wisconsin should be in top third in venture capital
5. Third Wave files countersuit vs. Digene in patent case
6. Third Wave reports net loss of $18.9M for 2006
7. Stratagene to pay Third Wave $10.75M in patent case
8. Third Wave responds to Digene patent lawsuit
9. Third Wave seeks approval of Cystic Fibrosis test
10. Third Wave Technologies to raise $14.9M through private debt
11. Venture capital above $6B for third straight quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... ALBANY, New York , March 23, 2017 ... animal blood plasma products and derivatives market is fragmented due to the ... large players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, ... clear leader, these three companies, collectively, held more than 76% of ... ...
Breaking Biology Technology:
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/20/2017)... Germany , March 20, 2017 At this ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG ... is this year,s CeBIT partner country. At the largest German ... biometrics in use: fingerprint, face and iris recognition as well as DERMALOG´s ... ...
(Date:3/13/2017)... Germany , March 13, 2017 Future of security: ... ... DERMALOGs Face Matching enables to match face ... forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric ...
Breaking Biology News(10 mins):